One year after the Medicaid continuous enrollment provision ended, 19.2 million people have been disenrolled from Medicaid, according to KFF. This is higher than many expected, and experts have mixed reviews on how they think this process has gone.
Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.
This technology can result in reduced readmission rates, increased patient satisfaction, and a consistent flow of post-acute care revenue, especially in rural areas.
At HIMSS24, Heather O’Sullivan, Mass General Brigham’s president of healthcare at home, said that the health system wants to move 10% of all its medical patients to the home. She argued that there is “no greater model of care for being patient-centric,” and highlighted the care modality’s ability to alleviate burnout for some healthcare workers.
Through a new partnership, FOLX members can gain access to crisis counselors through Crisis Text Line in addition to their support from the FOLX Health care team.
Novocure said its “Tumor Treating Fields” met the main goal of a pivotal study enrolling non-small cell lung cancer patients with brain metastases. However, results for the electricty-based treatment fell short of statistical significance on several secondary endpoints.